Stögmann Elisabeth, Schmidt Reinhold
Department of Neurology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090, Vienna, Austria.
Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036, Graz, Austria.
Wien Klin Wochenschr. 2025 Mar;137(5-6):182-188. doi: 10.1007/s00508-024-02466-7. Epub 2024 Nov 6.
Amyloid-beta (Aβ) antibody treatment has emerged as a promising approach for the treatment of Alzheimer's disease (AD), targeting the accumulation of Aβ plaques, which are a hallmark of the disease. This review provides an update on recent clinical trial data, highlighting the efficacy and safety of various antibodies targeting Aβ. Recent trials have demonstrated that certain Aβ antibodies can reduce amyloid plaques and slow cognitive decline in patients with early AD. Key findings from trials of drugs are discussed, including their mechanisms of action, dosing regimens, and observed side effects. The potential for Aβ antibody therapy to be integrated into routine clinical practice is also explored. While Aβ antibody therapy represents a significant advancement in AD treatment, ongoing research is needed to optimize their use and understand their long-term impact. This review underscores the importance of personalized medicine in AD and the need for continued innovation in therapeutic strategies.
β-淀粉样蛋白（Aβ）抗体治疗已成为治疗阿尔茨海默病（AD）的一种有前景的方法，其针对的是Aβ斑块的积累，而Aβ斑块是该疾病的一个标志。本综述提供了近期临床试验数据的更新，突出了各种靶向Aβ的抗体的疗效和安全性。近期试验表明，某些Aβ抗体可减少早期AD患者的淀粉样斑块并减缓认知衰退。讨论了药物试验的主要发现，包括其作用机制、给药方案和观察到的副作用。还探讨了Aβ抗体疗法整合到常规临床实践中的潜力。虽然Aβ抗体疗法代表了AD治疗的重大进展，但仍需要进行持续研究以优化其使用并了解其长期影响。本综述强调了个性化医疗在AD中的重要性以及治疗策略持续创新的必要性。
